Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR-IL12-CART in metastatic colorectal cancer
NCT03542799Phase 1Unknown
- Sponsor
- Shenzhen Second People's Hospital
- Start
- May 2018
- Primary completion
- May 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of egfr-il12-cart in metastatic colorectal cancer (mCRC), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Occurrence of study related adverse events at 24 weeks. Status: unknown.
02
Drugs
egfr-il12-cart
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03542799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542799.